Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chia-Chi Lin

Showing results (141-150 of 231) with videos related to

Pageof 24
Sort By:
The Oncologist|November 27, 2020
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid TumorsHer-Shyong Shiah, Nai-Jung Chiang, Chia-Chi Lin, et al.
Frontiers in Oncology|July 18, 2022
B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaJhe-Cyuan Guo, Chia-Lang Hsu, Yen-Lin Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1Anthony W Tolcher, John Sarantopoulos, Amita Patnaik, et al.
Anticancer Research|March 2, 2018
Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative ChemoradiotherapyJhe-Cyuan Guo, Chia-Chi Lin, Ta-Chen Huang, et al.
BMJ Open|August 29, 2024
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre studyChia-Chi Lin, Giuseppe Curigliano, Armando Santoro, et al.
Plos Genetics|December 3, 2025
A fly model of SCA36 reveals combinatorial neurotoxicity of hexanucleotide and dipeptide repeatsCheng-Tsung Hsiao, Ssu-Ju Fu, Ting-Ni Guo, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trialRoss A Soo, Eng Huat Tan, Hidetoshi Hayashi, et al.
Molecular Cancer Therapeutics|March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid TumorsJohn H Strickler, Patricia LoRusso, Ravi Salgia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 16, 2010
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptorsChia-Chi Lin, Hsin-Hsin Hsu, Chia-Tung Sun, et al.
British Journal of Cancer|August 3, 2023
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancerValentine M Macaulay, Simon Lord, Syed Hussain, et al.
Pageof 24

Showing results (141-150 of 231) with videos related to

Sort By:
Pageof 24
The Oncologist|November 27, 2020
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid TumorsHer-Shyong Shiah, Nai-Jung Chiang, Chia-Chi Lin, et al.
Frontiers in Oncology|July 18, 2022
B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaJhe-Cyuan Guo, Chia-Lang Hsu, Yen-Lin Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1Anthony W Tolcher, John Sarantopoulos, Amita Patnaik, et al.
Anticancer Research|March 2, 2018
Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative ChemoradiotherapyJhe-Cyuan Guo, Chia-Chi Lin, Ta-Chen Huang, et al.
BMJ Open|August 29, 2024
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre studyChia-Chi Lin, Giuseppe Curigliano, Armando Santoro, et al.
Plos Genetics|December 3, 2025
A fly model of SCA36 reveals combinatorial neurotoxicity of hexanucleotide and dipeptide repeatsCheng-Tsung Hsiao, Ssu-Ju Fu, Ting-Ni Guo, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trialRoss A Soo, Eng Huat Tan, Hidetoshi Hayashi, et al.
Molecular Cancer Therapeutics|March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid TumorsJohn H Strickler, Patricia LoRusso, Ravi Salgia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 16, 2010
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptorsChia-Chi Lin, Hsin-Hsin Hsu, Chia-Tung Sun, et al.
British Journal of Cancer|August 3, 2023
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancerValentine M Macaulay, Simon Lord, Syed Hussain, et al.
Pageof 24